{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:15:48Z","timestamp":1782126948197,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T00:00:00Z","timestamp":1477267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T00:00:00Z","timestamp":1477267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1038\/leu.2016.299","type":"journal-article","created":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T06:43:50Z","timestamp":1477291430000},"page":"889-895","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis"],"prefix":"10.1038","volume":"31","author":[{"given":"R F","family":"Schlenk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Stegelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Gattermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Hebart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Schafhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I W","family":"Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Verbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F H","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kreipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Teleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Benner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Grie\u00dfhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,24]]},"reference":[{"key":"BFleu2016299_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nrc1323","volume":"4","author":"JB Bartlett","year":"2004","unstructured":"Bartlett JB, Dredge K, Dalgleish AG . The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4: 314\u2013322.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2016299_CR2","first-page":"549","volume":"11","author":"KL Gowin","year":"2015","unstructured":"Gowin KL, Mesa RA . Profile of pomalidomide and its potential in the treatment of myelofibrosis. Ther Clin Risk Manag 2015; 11: 549\u2013556.","journal-title":"Ther Clin Risk Manag"},{"key":"BFleu2016299_CR3","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","volume":"58","author":"C Galustian","year":"2008","unstructured":"Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2008; 58: 1033\u20131045.","journal-title":"Cancer Immunol Immunother"},{"key":"BFleu2016299_CR4","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1200\/JCO.2008.21.7356","volume":"27","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009; 27: 4563\u20134569.","journal-title":"J Clin Oncol"},{"key":"BFleu2016299_CR5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.21598","volume":"85","author":"RA Mesa","year":"2010","unstructured":"Mesa RA, Pardanani AD, Hussein K, Wu W, Schwager S, Litzow MR et al. Phase1\/-2 study of pomalidomide in myelofibrosis. Am J Hematol 2010; 85: 129\u2013130.","journal-title":"Am J Hematol"},{"key":"BFleu2016299_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/leu.2010.254","volume":"25","author":"KH Begna","year":"2011","unstructured":"Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 2011; 25: 301\u2013304.","journal-title":"Leukemia"},{"key":"BFleu2016299_CR7","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.leukres.2013.07.007","volume":"37","author":"N Daver","year":"2013","unstructured":"Daver N, Shastri A, Kadia T, Quintas-Cardama A, Jabbour E, Konopleva M et al. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res 2013; 37: 1440\u20131444.","journal-title":"Leuk Res"},{"key":"BFleu2016299_CR8","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.leukres.2014.06.015","volume":"38","author":"N Daver","year":"2014","unstructured":"Daver N, Shastri A, Kadia T, Newberry K, Pemmaraju N, Jabbour E et al. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res 2014; 38: 1126\u20131129.","journal-title":"Leuk Res"},{"key":"BFleu2016299_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S et al. International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437\u2013438.","journal-title":"Leukemia"},{"key":"BFleu2016299_CR10","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","volume":"108","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT et al. IWG for Myelofibrosis Research and Treatment (IWG-MRT). International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006; 108: 1497\u20131503.","journal-title":"Blood"},{"key":"BFleu2016299_CR11","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn. WHO Press: Geneva, Switzerland, 2008."},{"key":"BFleu2016299_CR12","volume-title":"ISCN (1995): An International System for Human Cytogenetic Nomenclature","author":"F Mitelman","year":"1995","unstructured":"Mitelman F (ed). ISCN (1995): An International System for Human Cytogenetic Nomenclature. Karger: Basel, Switzerland, 1995."},{"key":"BFleu2016299_CR13","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054\u20131061.","journal-title":"Lancet"},{"key":"BFleu2016299_CR14","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.","journal-title":"PLoS Med"},{"key":"BFleu2016299_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.leukres.2014.11.019","volume":"39","author":"AV Jones","year":"2015","unstructured":"Jones AV, Ward D, Lyon M, Leung W, Callaway A, Chase A et al. Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms. Leuk Res 2015; 39: 82\u201387.","journal-title":"Leuk Res"},{"key":"BFleu2016299_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3324\/haematol.2014.114157","volume":"100","author":"P Paschka","year":"2015","unstructured":"Paschka P, Schlenk RF, Gaidzik VI, Herzig JK, Aulitzky T, Bullinger L et al. ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. Haematologica 2015; 100: 324\u2013330.","journal-title":"Haematologica"},{"key":"BFleu2016299_CR17","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1200\/JCO.2011.39.2886","volume":"30","author":"VI Gaidzik","year":"2012","unstructured":"Gaidzik VI, Paschka P, Sp\u00e4th D, Habdank M, K\u00f6hne CH, Germing U et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol 2012; 30: 1350\u20131357.","journal-title":"J Clin Oncol"},{"key":"BFleu2016299_CR18","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/leu.2011.77","volume":"25","author":"F Stegelmann","year":"2011","unstructured":"Stegelmann F, Bullinger L, Schlenk RF, Paschka P, Griesshammer M, Blersch C et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia 2011; 25: 1217\u20131219.","journal-title":"Leukemia"},{"key":"BFleu2016299_CR19","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ng.621","volume":"42","author":"T Ernst","year":"2010","unstructured":"Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722\u2013726.","journal-title":"Nat Genet"},{"key":"BFleu2016299_CR20","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","volume":"28","author":"P Paschka","year":"2010","unstructured":"Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kr\u00f6nke J, Bullinger L et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010; 28: 3636\u20133643.","journal-title":"J Clin Oncol"},{"key":"BFleu2016299_CR21","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","volume":"119","author":"SJ Zhang","year":"2012","unstructured":"Zhang SJ, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 2012; 119: 4480\u20134485.","journal-title":"Blood"},{"key":"BFleu2016299_CR22","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","volume":"119","author":"FG R\u00fccker","year":"2012","unstructured":"R\u00fccker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012; 119: 2114\u20132121.","journal-title":"Blood"},{"key":"BFleu2016299_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.leukres.2010.07.015","volume":"35","author":"RP Gale","year":"2011","unstructured":"Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B et al. What are RBC-transfusion-dependence and -independence? Leuk Res 2011; 35: 8\u201311.","journal-title":"Leuk Res"},{"key":"BFleu2016299_CR24","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ . A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141\u20131154.","journal-title":"Ann Stat"},{"key":"BFleu2016299_CR25","unstructured":"R Development Core Team R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2009."},{"key":"BFleu2016299_CR26","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703\u20131708.","journal-title":"Blood"},{"key":"BFleu2016299_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/leu.2010.234","volume":"25","author":"D Caramazza","year":"2011","unstructured":"Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 2011; 25: 82\u201388.","journal-title":"Leukemia"},{"key":"BFleu2016299_CR28","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/j.1365-2141.2010.08275.x","volume":"150","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Rumi E, Elena C, Arcaini L, Merli M, Pascutto C et al. Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. Br J Haematol 2010; 150: 719\u2013721.","journal-title":"Br J Haematol"},{"key":"BFleu2016299_CR29","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1182\/blood-2010-04-279893","volume":"116","author":"G G\u00f6rg\u00fcn","year":"2010","unstructured":"G\u00f6rg\u00fcn G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010; 116: 3227\u20133237.","journal-title":"Blood"},{"key":"BFleu2016299_CR30","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nature15252","volume":"525","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li X et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 2015; 525: 389\u2013393.","journal-title":"Nature"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2016299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016299","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T04:13:32Z","timestamp":1718856812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,24]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["BFleu2016299"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.299","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,24]]},"assertion":[{"value":"21 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors\u2019 disclosures of potential conflict of interest. Research funding by Celgene.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}